Equillium (EQ) Net Margin (2023 - 2024)
Equillium (EQ) reported Net Margin of 131.92% for Q4 2024, down 10667.0% year-over-year from N/an in Q1 2024, and down 229085.64% quarter-over-quarter from 0.06% in Q3 2024.
Equillium (EQ) Net Margin (2023 - 2024) Analysis & Trends
Equillium (EQ) has 2 years of Net Margin data on file, last reported at 131.92% in Q4 2024.
- Net Margin for Q4 2024 came in at 131.92%, down 10667.0% year-over-year; the trailing twelve-month figure through Sep 2025 was 567.78% (down 55777.0% YoY), and the FY2024 annual result was 19.63%, up 1738.0% from the prior year.
- Net Margin slipped to 131.92% in Q4 2024 per EQ's latest filing, from 0.06% in the prior quarter.
- Over five years, Net Margin peaked at 3.38% in Q2 2024 and troughed at 131.92% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.82% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Equillium | 293.17 Mn | 232.78 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -131.92% |
| Sep 30, 2024 | -0.06% |
| Jun 30, 2024 | 3.38% |
| Mar 31, 2024 | -25.58% |
| Dec 31, 2023 | -25.25% |
| Sep 30, 2023 | -41.83% |
| Jun 30, 2023 | -36.64% |
| Mar 31, 2023 | -44.37% |